- Orexin-A inhibits capsaicin-induced changes in cyclooxygenase-2 and brain-derived neurotrophic factor expression in trigeminal nucleus caudalis of rats
-
Kooshki R, Abbasnejad M, Esmaeili Mahani S, Raoof M, Moeini Aghtaei MM, Dabiri S
- KMID: 2417955
- Korean J Pain.
- 2018 Jul;31(3):174-182.
- doi: 10.3344/kjp.2018.31.3.174
BACKGROUND: The trigeminal nucleus caudalis (Vc) is a primary central site for trigeminal transmitting. Noxious stimulation of the trigeminal nociceptors alters the central synaptic releases and neural expression of some... -
- CITED
-
- Close
- SHARE
-
- Close
- A Novel Bio-Psychosocial-Behavioral Treatment Model of Panic Disorder
-
Park SC, Kim YK
- KMID: 2438154
- Psychiatry Investig.
- 2019 Jan;16(1):4-15.
- doi: 10.30773/pi.2018.08.21.1
To conceptualize a novel bio-psychosocial-behavioral treatment model of panic disorder (PD), it is necessary to completely integrate behavioral, psychophysiological, neurobiological, and genetic data. Molecular genetic research on PD is specifically... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study
-
Hatano M, Kamei H, Inagaki R, Matsuzaki , Hanya M, Yamada S, Iwata N
- KMID: 2412387
- Clin Psychopharmacol Neurosci.
- 2018 May;16(2):184-189.
- doi: 10.9758/cpn.2018.16.2.184
OBJECTIVE: Suvorexant is a novel hypnotic drug that does not interact with the conventional γ-aminobutyric acid (GABA)-A receptor. We investigated the method by which suvorexant was introduced in insomnia patients... -
- CITED
-
- Close
- SHARE
-
- Close
